Work

Circulating miRNA deregulation in diffuse intrinsic pontine glioma: diagnostic classification and biological pathway insights

Year: 2026
Type: article
Abstract: Diffuse intrinsic pontine glioma (DIPG)/pontine diffuse midline glioma (DMG) remains one of the most lethal pediatric brain tumors. Tissue access is limited, and clinically useful non-invasive biomarkers are lacking. We investigated whether circulating serum miRNAs could generate a diagnostic signature discriminating DIPG from pediatric patients with non-CNS malignancies and provide insight into disease-associated molecular programs. Serum miRNA profiles from 47 DIPG patients and 42 pediatric non-DIPG controls with a history of non-CNS malignancies were analyzed.The cohort comprised a training set (23 DIPG patients and 21 controls) and an independent retrospective test set (24 DIPG patients and 21 controls). A LASSO logistic regression classifier was developed in the training set using internal 10-fold cross-validation. The final 15-miRNA model, including its classification rule, was locked before evaluation in the test set. Samples with a predicted probability of DIPG ≥ 0.5 were classified as DIPG. Differential miRNA expression was analyzed separately in training and test sets as a biological discovery layer, and concordantly deregulated candidates were prioritized for target prediction and pathway enrichment. LASSO logistic regression retained a 15-miRNA signature. Internal cross-validation during model development yielded 97.7% accuracy (43/44), an estimate that may be optimistic because it was obtained during model selection. Independent evaluation of the locked classifier yielded 95.6% accuracy (43/45; 95% CI, 84.9–99.5%), 100.0% sensitivity (24/24; 95% CI, 85.8–100.0%), and 90.5% specificity (19/21; 95% CI, 69.6–98.8%). Predicted probabilities showed strong class separation, with high DIPG-class probabilities in all DIPG samples and low probabilities in most controls. Differential expression analysis identified 70 significant miRNAs in the training set (58 upregulated and 12 downregulated in DIPG) and 65 in the test set (55 upregulated and 10 downregulated). A biologically prioritized six-miRNA panel implicated neural development, axonogenesis, cadherin signaling, MAPK/Ras signaling, TGF-beta signaling, Wnt signaling, and immune-related programs. Serum circulating miRNAs discriminated DIPG patients from pediatric oncologic patients with high accuracy in this retrospective cohort. The 15-miRNA model provides a diagnostic signature, whereas differential expression and pathway analyses highlight DIPG-associated molecular and microenvironmental processes. These findings support prospective validation of circulating miRNA profiling as a minimally invasive biomarker strategy for DIPG.
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,890
OpenAlex ID: W7237364759
FWCI:
Cites:
Cited by:
Related to: